Drug Resistance Updates

Drug Resistance Updates is a bimonthly peer-reviewed journal published by Churchill Livingstone, an imprint of Elsevier, established in 1998, covering drug resistance in infectious disease and cancer alongside strategies to overcome it, with a 2025 Journal Impact Factor of 22.0.《耐药性进展》是由爱思唯尔（Elsevier）旗下（Churchill Livingstone）出版的双月刊同行评审期刊，1998 年创刊，关注传染病与癌症中的耐药性及其克服策略，2025 年影响因子为 22.0。

Scope

• It publishes original research, commentary and expert reviews on important developments in drug resistance in infectious disease and cancer.该刊刊载有关传染病与癌症耐药性重要进展的原创研究、评论与专家综述。
• It also covers novel drugs and strategies designed to overcome drug resistance.该刊亦关注旨在克服耐药性的新药与新策略。
• It addresses both the basic research and the clinical aspects of drug resistance.该刊兼顾耐药性的基础研究与临床方面。
• Its subject matter spans molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology and clinical medicine.其主题涵盖分子生物学、生物化学、细胞生物学、药理学、微生物学、临床前治疗学、肿瘤学与临床医学。^[1]
• Review articles are written by invited leaders in the field, while original research articles are welcomed from all authors.综述文章由受邀的领域领军学者撰写，原创研究文章则面向所有作者征稿。
• Its scope includes antimicrobial and anticancer chemotherapy resistance mechanisms and their translational implications.其范围涵盖抗微生物与抗肿瘤化疗的耐药机制及其转化意义。^[2]

History

• The journal was first published in 1998 by Churchill Livingstone, with editorial offices in Edinburgh and Philadelphia.该刊于 1998 年由（Churchill Livingstone）创刊，编辑部最初设于爱丁堡与费城。
• Its original subtitle referred to reviews and commentaries in antimicrobial and anticancer chemotherapy, reflecting an early review-oriented identity.其最初的副标题定为「抗微生物与抗肿瘤化疗的综述与评论」，反映出该刊早期以综述为重的定位。
• Churchill Livingstone later became an imprint of Elsevier, which now publishes the journal.（Churchill Livingstone）后来成为爱思唯尔（Elsevier）的出版品牌，该刊现由（Elsevier）出版。
• The journal grew to publish six issues a year in a bimonthly schedule, combining invited reviews with original papers.该刊发展至每年出版六期，以双月刊形式发行，内容兼顾受邀综述与原创论文。
• Its 2025 Journal Impact Factor stands at 22.0, after 21.7 in 2024 and 22.841 in 2022.其 2025 年影响因子为 22.0，此前 2024 年为 21.7、2022 年为 22.841。
• It is indexed in MEDLINE, the Science Citation Index Expanded and Scopus.该刊被（MEDLINE）、（Science Citation Index Expanded）与（Scopus）收录。

Editors

• The Editor-in-Chief is Zhe-Sheng Chen, a professor of pharmaceutical sciences at St. John's University in New York.现任主编为（Zhe-Sheng Chen），是纽约（St. John's University）的药学教授。
• His research focuses on cancer multidrug resistance and the development of novel anticancer drugs, with more than 300 publications to his name.其研究聚焦肿瘤多药耐药与新抗癌药物研发，发表论文逾 300 篇。
• He has held numerous editorial roles, including associate editor positions at several journals.他曾担任多种编辑职务，包括若干期刊的副编辑。
• The journal relies on an international editorial board and on invited expert reviewers drawn from oncology, microbiology and pharmacology.该刊依托国际化的编委会，以及来自肿瘤学、微生物学与药理学的受邀专家审稿人。
• Review articles are commissioned from leading researchers, while research submissions undergo external peer review.综述文章约请顶尖研究者撰写，研究投稿则接受外部同行评审。